MOS Launches Enzyme-Based Residue Management Product

The Mosaic Company’s MOS Mosaic Biosciences unit recently launched Renuvis Enzara, a new residue management solution designed to accelerate crop residue decomposition and help growers with plant-ready field conditions sooner.

The product addresses challenges associated with increasing residue levels resulting from higher-yielding hybrids, no-till practices and continuous corn production. Heavy residue can add tillage passes, reduce planting capacity and contribute to uneven emergence and inconsistent seed depth.

Enzara uses endoglucanase enzyme technology to target the structural fibers holding crop residue together. Unlike microbial-based solutions that require time to colonize, the enzyme begins working even under cold conditions, including temperatures as low as 32 degrees Fahrenheit. By creating more entry points for naturally occurring soil microbes, the product is designed to manage more residue.

The solution can also complement current residue management practices by reducing residue, lowering fuel consumption and can be applied in fall or spring and is compatible with fertilizer and herbicide tank mixes, eliminating the need for an additional application pass. The launch expands Mosaic Biosciences' product portfolio and highlights the company's focus on technology-driven solutions that can improve farm productivity and operational efficiency.

MOS’ shares have lost 28.3% over the past year compared with the industry’s 45.1% decline.

Image Source: Zacks Investment Research

MOS’ Zacks Rank & Key Picks

MOS currently carries a Zacks Rank #4 (Sell). 

Some better-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. NOPMF, Carpenter Technology Corporation CRS and Avient Corporation AVNT.

While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 94.3% over the past year.

The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.

The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 16.5% over the past year.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com